Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages

Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages

Abstract Background Cancer immunotherapy, particularly immune checkpoint inhibitors (ICBs) such as anti-PD-1 antibodies, has revolutionised cancer treatment, although response rates vary among patients. Previous studies have demonstrated that caerin 1.1 and 1.9, host-defence peptides from the Austra...

Full description

Bibliographic Details
Main Authors: Quanlan Fu, Yuandong Luo, Junjie Li, Hejie Li, Xiaosong Liu, Zhu Chen, Guoying Ni, Tianfang Wang
Format: Article
Language:English
Published: BMC 2024-10-01
Series:Journal of Translational Medicine
Subjects:
Caerin peptide
B16 cell
Melanoma
Macrophage
cDC1
CD4+CD8+ T cell
Online Access:https://doi.org/10.1186/s12967-024-05763-x

Internet

https://doi.org/10.1186/s12967-024-05763-x

Similar Items